Thus, inhibition of IL-4 by dupilumab may lead to enthesitis and inflammatory arthritis similar to how it occurs in spondyloarthropathy conditions such as axial spondyloarthritis and psoriatic arthritis. Here, IL4 is linked to spondyloarthropathy.